Dr. Milan Chag

Managing Director and Senior Interventional Cardiologist at Care Institute of Medical Sciences (CIMS Hospital), Ahmedabad, Gujarat in India

Managing Director

Dr. Milan Chag is managing director at CIMS Hospital which was recently rated the best multispeciality hospital of Gujarat for 2018.

Excellent Heart Healer

Dr. Milan Chag is one of the best cardiologists in India. He has an excellent success rating when dealing with heart failure problems in patients of all age groups.

Expert at Removing Blockages

Dr. Milan Chag is an expert when it comes to removing blockages that stop normal blood flow to the heart.

Top Educator & Teacher

Dr. Milan Chag is an educator. He has managed medical education conferences just JIC and delivered lectures to patients and doctors alike. He has travelled around the world to imparct knowledge.

Pioneer & Expertise

Dr. Milan Chag is a pioneer in establishing coronary, non-coronary, paediatric and structural heart disease interventional programs all over Gujarat and in India.

Award Winning Doctor & Cardiologist

Dr. Milan Chag has been awarded “Distinguished Service Award in Cardiovascular Science, Medicine and Surgery” by International Academy of Cardiovascular Sciences, Winnipeg, Canada in February 2011.

9

Expert in Angioplasty

Dr. Milan Chag is recognized as one of the top angioplasty experts in India.

9

Expert in Delivering Stents Safely

Dr. Milan Chag is an expert when it comes to the usage of stents during angioplasty.

9

Congenital Heart Disease Expertise

Dr. Milan Chag is a top heart specialist when its related to CHD in patients of all ages.

9

Largest Cardiac Team in Gujarat

Dr. Milan Chag is the director of the Heart Failure Clinic which includes the top and best cardiac doctors and surgeons in Gujarat and includes the largest cardiac team under one roof in the state of Gujarat.

Dr. Milan Chag – International Clinical Trials by an Expert Cardiologist in Ahmedabad Gujarat India

International Clinical Trials

1 Co-Investigator for RUBY registry (For India) To evaluate Percusurge / Guardwire Distal Protection Device (Presented by Dr. Aman, Switzerland) Presented TCT October 2003
2 Co-Investigator at Sterling Hospital for Extract-TIMI 25 Multicentre multinational Trial (2003). Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction –Study 25. Presented at ACC 06. Trial completed
3 To Evaluate the Efficacy and Safety of Fondaparinux versus Enoxaparin in the Acute Treatment of Unstable Angina or Non ST-Segment Elevation Myocardial Infarction Acute Coronary Syndromes. Presented in ESC, Stockholm, Sweden. Trial completed
4 Co-Investigator for OASIS-6 Trial (2004). To Evaluate the Efficacy and Safety of Fondaparinux Sodium versus Control Therapy and Glucose-Insulin-Potassium Infusion versus Control in Broad Range in Patients with ST -Segment Elevation Acute Myocardial Infarction. Presented at ACC 06. Trial completed
5 Co-Investigator for TRUST Trial (2004). To Evaluate the Safety and Efficacy of Intravenous Remodulin® in Patients (in India) with Pulmonary Arterial Hypertension (PAH) in 12-week. Trial completed
6 Principal Investigator for Paediatric Hypertension Trial (2005). Dose Ranging Study to Evaluate the Safety and Efficacy of Olmesartan medoxomil in Children and Adolescents with Hypertension. Trial completed
7 Co-Investigator for TRUST Trial at SAL Hospital , Ahmedabad
India.
Prostacyclin Analogue in Pulmonary Hypertension Trial completed
8 Co-Investigator for Hypercholesterol study (NK-104-301) at The Heart Care Clinic/CIMS (2005). Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients with Primary Hypercholesterolemia or Combined Dyslipidemia. Trial completed
9. Co-Investigator for Neovasc Reducer™ Pilot Study, First in human: (2005). To Evaluate the Safety of the Neovasc Reducer™ in the Treatment of Ischemic Heart Disease (IHD), Controlled Narrowing of the Coronary Sinus. Presented at TCT, 2005. Trial completed
10 Co-Investigator For PAPIRUS Trial: Pilot Study, First in Human: Apollo Hospital (2005). Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal (REMON Device). Trial completed
11 Co-Investigator for Export study (2006). Flow Improvement in Patients with Acute Myocardial Infarction Undergoing Either Conventional Stenting or a Strategy of Primary Aspiration Followed by Stenting Using the Export® Aspiration Catheter: a Prospective, Randomized, Controlled Study. Trial completed
12 Co-Investigator for E-five registry (for India) (2006). To Evaluate the ‘Real World’ Clinical Performance of the Medtronic Endeavor™ ABT-578 Eluting Coronary Stent System. Trial completed
13 Co-Investigator for RELY study (2006). Randomized Evaluation of Long Term Anticoagulant Therapy Comparing Efficacy and Safety of Two Blinded Doses of Dabigatran etexilate with Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients with  Non-Valvular Atrial Fibrillation : Prospective, Multi-Centre, Parallel Group, Non-Inferiority Trial. Trial completed
14 Co- Investigator for RELY ABLE study (2009). Long Term Multi-center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation Who Completed the RELY Trial and a Cluster Randomized Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes. Trial completed
15 Co-Investigator for Hypercholesterolemia study (NK-104-307) at The Heart Care Clinic/CIMS (2006). Open Label, Long-Term (1year) Extension Study of Pitavastatin 4 mg QD in Patients with Primary Hypercholesterolemia or Combined Dyslipidemia. Trial completed
16 Co-Investigator for e-SELECT Registry (2007). The e-SELECT Registry: A Multicenter Post Marketing Survelliance. Trial completed
17 Co-Investigator for Early ACS trial (2007). Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS). Trial completed
18 Co-Investigator for PLATO trial (2007). A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compares with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO – A study of PLATelet inhibition and Patient Outcomes.] Trial completed
19 Co-Investigator for OASIS- 7 trial (2007). Randomized, Multinational, Double-blind study, Comparing a High Loading Dose Regimen of Clopidogrel versus Standard Dose in Patients with Unstable Angina or Non-ST Segment Elevation Myocardial Infarction Managed with an Early Invasive Strategy. Trial completed
20 Co- Investigator for New Guidewire (2007). First in Man: A Feasibility Study to Evaluate Safety and Efficacy of New Guidewire for Crossing Total Occlusions in Coronary Arteries. Trial completed
21 Co-Investigator for Paediatric Hypertension Trial, The Heart Care Clinic/CIMS, Ahmedabad (2007). A Randomized, Double blind, Placebo-Controlled, Multicenter, Parallel Study Assessing the Efficacy, Safety, and Dose Response of Ramipril for the Treatment of Hypertension in Children and Adolescents. Trial completed.
22 Co-Investigator for Aristotle Trial at The Heart Care Clinic/CIMS, Ahmedabad (2007). Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation: Active Controlled Randomized Double Blind Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Subject with  Non-valvular Atrial Fibrillation. Trial completed.
23 Co-Investigator for Rocket Trial at The Heart Care Clinic/CIMS, Ahmedabad (2007). Multicenter, Randomized, Double-blind – Dummy, Parallel-group, Non-inferiority Trial Comparing the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY 59-7939) with Adjusted-dose Oral Warfarin for the Prevention of Stroke and Non-central-nervous-system Systemic Embolism in Subjects with Non-valvular Atrial Fibrillation. Trial completed
24 Co-Principal Investigator for PROTECT Trial (2007). Patient Related Outcomes with Endeavor versus Cypher Stenting Trial: Prospective, Multicenter, Randomized, Two-arm, Open-label Trial. Trial completed
25 Co-Investigator for TMC-CAN-05-02 (2007). A Clinical Trial Comparing Cangrelor to Clopidogrel in Subject who Require Percutaneous Coronary Intervention. Trial completed
26 Co-Investigator for TMC-CAN-05-03 (2008). A Clinical Trial Comparing Treatment with Cangrelor (in combination with usual care) to Usual Care in Subjects who Require Percutaneous Coronary Intervention. Trial completed
27 Co-Investigator for RELY AF Registry (2008). Risk Factors, Treatments and Outcomes for Emergency Department Patients with Atrial Fibrillation in Multiple Regions of the World. Trial completed
28 Co-Investigator for CL (Ivabradine) at The Heart Care Clinic/CIMS (2008). Evaluation of the Anti-anginal Efficacy. Trial completed
29 Co-Investigator for RE-DEEM at The Heart Care Clinic/CIMS (2008). Randomized Dabigatran Etexilate Dose Finding Study in Patients with Acute Coronary Syndromes Post Index Event with Additional Risk Factors for Cardiovascular Complications also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Group Dose Escalation Trial. Trial completed
30 Co-Investigator for Magellan Trial (2008). A Multicenter, Randomized, Parallel-group Efficacy Superiority Study in Hospitalize Medically Ill Patients Comparing Rivaroxaban with Enoxaparin. Trial completed.
31 Co-Investigator for Borealis Trial at The Heart Care Clinic/CIMS Ahmedabad (2008). A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) with Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patient with Atrial Fibrillation. Trial completed.
32 Co-Investigator for Freedom-PAH at The Heart Care Clinic/CIMS. FREEDOM UT –15C Studies (TDE-PH-302 and TDE-PH-304) Conducted by United Therapeutics. Follow ups Ongoing
33 Co-Investigator for ORBIT – 1. Pilot Study to Evaluate the Safety & Performance or the Diamondback 360TM Orbit Atherectomy System in Treating De Novo Calcified Coronary Lesions – Orbit –I. Trial completed
34 Co-Investigator for AVERROES at The Heart Care Clinic/CIMS. CV 185-048: A Phase 3, Active (Aspirin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation. Trial Completed.
 35 Co-Investigator for Red-HF at The Heart Care Clinic/CIMS. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction  and Anemia –. Trial Completed.
36 Co-Investigator for TAK-442-202 at The Heart Care Clinic/CIMS. A Phase II, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects with Acute Coronary Syndrome. Trial completed.
37 Co-Investigator for EISAI-202 at The Heart Care Clinic/CIMS. A Randomized, Double-Blind Placebo Controlled Study of the Safety and Tolerability of E5555 and its Effect on Clinical Event and Biomarkers in Patient with Non-ST Segment Elevation Acute Coronary Syndrome. Trial completed
38 Co-Investigator for E-Resolute at the Heart Care Clinic/CIMS. Evaluation of the Endeavor Resolute Zotarolimus -Eluting Coronary Stent System in a ‘Real World’ Patient Population. Follow-up Ongoing
39 Co-Investigator of RIVAROXABAN at The Heart Care Clinic/CIMS. Randomized, Double Blind, Placebo Controlled, Event Driven, Multi-Center Study To Evaluate The Efficacy And Safety of Rivaroxaban in Subjects With Recent ACS. Trial completed
40 Co-Investigator of Pfizer PAH at The Heart Care Clinic/CIMS B1321001. A Phase 3, Multi-center, Randomized, Double Blind, Placebo Controlled, Safety and Efficacy Study of Sitaxsentan Sodium in Subjects with Pulmonary Arterial Hypertension. Trial completed
41 Co-Investigator of Pfizer PAH at The Heart Care Clinic/CIMSB1321002. A Phase 3, Multi Center, Open Label Study To Evaluate The Long Term Safety of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension. Trial completed
42 Co-Investigator of Pfizer PAH at The Heart Care Clinic/CIMSB1321003. A Phase 3, Multi Center, Randomized, Double Blind, Efficacy and Safety Study of Monotherapy Sitaxsentan Sodium versus Combination Therapy with Sitaxsentan Sodium and Sildenafil Citrate in Subjects with Pulmonary Arterial Hypertension who have Completed Study B1321001. Trial completed
43 Principal Investigator of LPL STABILITY at The Heart Care Clinic/CIMS. A Clinical Outcome Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Event (MACE). Trial Completed.
44 Co-Investigator of OASIS-8 at The Heart Care Clinic/CIMS. A Prospective Study Evaluating the Safety of Two Regimens of Adjustive Intravenous UFH PCI in High Risk Patients with UA/NSTEMI Initially Treated with Subcutaneous Fondaparinux and Referred for Early Coronary Angiography. Trial Completed.
45 Co-Investigator of STEM CELL. Trial Completed.
46 Co-Investigator for RUBY 1Trial at The Heart Care Clinic /CIMS Ahmedabad (2010). A Randomized, Double Blind, Placebo Controlled, Multicentre and Parallel Group Study of the Safety, Tolerability, and Efficacy of YM150 in Combination with  Standard Treatment in Secondary  Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes. Trial Completed.
47 Co-Investigator for AmarinTrial at The Heart Care Clinic/CIMS Ahmedabad (2010). A phase 3, Multi centre, Placebo Controlled, Randomized, Double Blind, 12 Week Study with an Open Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients with Fasting Triglyceride Levels > 500 mg/dl and <  2000 mg/dl. Trial Completed.
48 Co-Investigator for AppraiseTrial at The Heart Care Clinic/CIMS Ahmedabad (2010). A Phase III, Randomized, Double Blind, Evaluation of the Safety and Efficacy of Apixaban in Subjects with a Recent Acute Coronary Syndrome. Trial Completed.
49 Co-Investigator for SAS HF Trial at The Heart Care Clinic/CIMS Ahmedabad (2008). South Asian Systolic Heart Failure Registry. Trial Completed.
50 Co-Investigator for TRAC HF Trial at The Heart Care Clinic/CIMS Ahmedabad (2009). TRAC HF: Ambulatory Monitoring Using External Physiological Sensors in Heart Failure Patients. Trial Completed.
51 Co-Investigator for DOT HF Trial at The Heart Care Clinic/CIMS Ahmedabad (2009). DOT-HF- Diagnostic Outcome Trial in Heart Failure. Trial completed
52 Co-Investigator for T BEST D Trial at The Heart Care Clinic/CIMS Ahmedabad (2009). T-BEST-D: Temporary Bronchial Epicardial Stimulation – Defibrillation Clinical Study Version dated: June 28, 2009. Trial completed
53 Co-Investigator for ALECARDIO Trial at The Heart Care Clinic/CIMS Ahmedabad (2010). A phase 3 Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study Cardiovascular Outcome Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with a Recent Acute Coronary Syndrome ( ACS) Event and Type 2 Diabètes Mellites (T2D). Trial completed
54 Co-Investigator for TIMI 52 Trial at The Heart Care Clinic / CIMS Ahmadabad (2010). A Phase 3 Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study of Darapladib versus Placebo in Subject Following Acute Coronary Syndrome  to Compare the Incidence of Major Adverse Cardiovascular Events. Trial completed
55 Co-Investigator for SOLISTICE trial at CIMS Hospital Ahmadabad (2011). A Randomized ,Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing with GW856553 and its Effects on Inflammatory Markers, Infract Size, and Cardiac Function in Subjects with Myocardial Infarction without ST Segment Elevation. Trial completed
56 Co-Investigator for CANVAS study at CIMS Hospital Ahmadabad (2011). A Randomized. Double-blind, Parallel, Placebo-Controlled, Multicenter Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus. The CANVAS Trial (CANagliflozin cardioVascular Assessment Study). Follow ups Ongoing.
57 Co-Investigator of study ATTAIN at CIMS Hospital Ahmadabad (2011). A Prospective, Non-randomized, Multi-center, Post-market, Global Clinical Trial to Assess Left-heart Lead Implant and Complication Rate Using the Medtronic Attain Family of Left-heart Leads and Delivery Catheters. Trial Completed.
58 Co-Investigator for TIMI 53 at CIMS Hospital Ahmadabad (2011). A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Sexagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patient with Type 2 Diabetes. Trial Completed.
59 Co-Investigator of study OPTIMIND at CIMS Hospital Ahmadabad (2011). Clinical Outcome of Pacemaker Patients According to Pacing Modality and Primary Indications. Trial Completed.
60 Co-Investigator of study SST at CIMS Hospital Ahmadabad (2011). The Pain Free SST (Smart Shock Technology) Clinical Study. Trial Completed.
61 Co-Investigator for VISTA 16 study at CIMS Hospital Ahmedabad (2011). Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndrome (ACS). VISTA-16: Vascular Inflammation Suppression to Treat Acute coronary syndrome for 16 weeks. Trial Completed.
62 Co-Investigator for TAO study at CIMS Hospital Ahmedabad (2011). Randomized, Double-blind, Triple-dummy Trial to Compare the Efficacy of Otamixaban with Unfractionated Heparin + Eptifibatide, in Patients with Unstable Angina/Non ST Segment Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy”. Trial Completed.
63 Co-Investigator for APOLLO study at CIMS Hospital Ahmedabad (2011). A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO). Trial Completed.
64 Co-Investigator for DELIVER study at CIMS Hospital Ahmedabad (2011). DELiverability of Resolute Integrity Stent In all- Comer Vessels and Cross Over Stenting”. Trial Completed.
65 Co-Investigator for EPICOR ASIA study at CIMS Hospital Ahmedabad (2011). Long term follow up of antithrombotic management patterns In Acute CORonary Syndrome patients in Asia. Trial Completed.
66 Co- Investigator for REMOTE-EVIA study at CIMS Hospital Ahmedabad (2011). Registry for Pacemaker Offering Therapy Enhancement- EVIA. Trial Completed.
67 Co-Investigator for ABSORB Extend (2011) A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold in the treatment  of Subjects with de novo Native Coronary Artery Lesions. Trial Completed.
68 Co- Investigator for IHRS study at CIMS Hospital Ahmedabad (2011). Indian Heart Rhythm Society (IHRS) Registry of Atrial Fibrillation: Patient Characteristics and Clinical Management Practices. Trial Completed.
69 Co-Investigator for SureScan Pacing System Post-Approval Study at CIMS Hospital, Ahmedabad (2012). Trial Completed.
70 Co-Investigator for BISO-CAD(2012). A study to investigate the association between resting heart rate (HR) and prognosis of patients with Coronary Artery Disease (CAD) treated with bisoprolol . Trial Completed.
71 Co-Investigator for IMPROVE-Brady study at CIMS Hospital, Ahmedabad (2012). Recruitment Ongoing
72 Co-Investigator for Medtronic Symplicity (2013) HTN-INDIA (CIP: 10054637DOC):  Single-arm Study of Symplicity™ Renal Denervation System in Patients with Uncontrolled HyperTensioN in India – HTN-India. Trial Completed.
73 Co-Investigator for Panorama 2 Registry at CIMS Hospital, Ahmedabad (2012). Medtronic CRDM Implantable Cardiac Device Long Term Registry. 73.Follow up Ongoing
74 Co-Investigator for CAD-PAD Registry at CIMS Hospital, Ahmedabad (2013). Coronary and Peripheral Artery Disease Registry. Trial Completed.
75 Co-Investigator for A Double-blind, Randomized, Placebo controlled, multicenter study assessing the impact of additional LDL-Cholesterol reduction on Major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease. Study Completed.
76 Co-Investigator for To Evaluate The Role Of Radiation Protection Technology (CardiotrapTM) In Improving Radiation Safety In Diagnostic And Interventional Percutaneous Cardiology Procedures. Investigator Initiated Study. Recruitment Ongoing.
77 Co-Investigator for Safety and Efficacy of Axiostat® hemostatic dressing on radial access after percutaneous procedure: A comparative open label study. Investigator Initiated Study. Recruitment Ongoing.
78 Co- Investigator for A Phase III, International, Multi-Centre, Randomized, Double-Blinded, Placebo-Controlled, Clinical Worsening study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background oral Monotherapy. Recruitment Ongoing.
79 Co- Investigator for An Open-Label Extension study of UT- 15C in subjects with Pulmonary Arterial Hypertension – A Long-Term Follow up to Protocol TDE-PH-310. Recruitment Ongoing.
80 Principal Investigator for A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus. Follow up Ongoing.
81 Co – Investigator for A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes. Follow up Ongoing.
82 Co-Investigator for TWILIGHT-Ticagrelor with Aspirin or alone in high risk patients after coronary intervention. Recruitment Ongoing.
83 Co-Investigator for REDUAL-PCI at CIMS Hospital, Ahmedabad (2014). A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting (RE-DUAL PCI). Follow up Ongoing.
84 Co-Investigator for Asian HF Registry at CIMS Hospital Ahmedabad (2012) Asian Sudden Cardiac Death in Heart Failure. Recruitment Ongoing.
85 Co-Investigator for PRISM at CIMS Hospital, Ahmedabad (2012). A Prospective Multi-Centre Registry to Investigate Safety and Effectiveness of  M’Sure-S (Sirolimus Eluting Coronary Stent). Follow up Ongoing.
86 Principal Investigator for E Resolute Asia at CIMS Hospital, Ahmedabad (2010). Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Patient Population with Long Lesion(s) and/or Dual Vessels in Asia; Prospective, Multi-center, Non-randomized Study. Follow up Ongoing.
87 Co-Investigator for INSPIRE-ELR at CIMS Hospital, Ahmedabad (2013). IdeNtifying High riSk Patients Post Myocardial Infarction with REduced Left Ventricular Function using External Loop Recorders. 87.Follow up Ongoing.
88 Co-Investigator for Improve SCA at CIMS Hospital, Ahmedabad (2014). For Improve Sudden Cardiac Arrest study. Recruitment Ongoing.
89 Co-Investigator for REPORT HF at CIMS Hospital, Ahmedabad (2014). International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure. Follow up Ongoing.

National Clinical Trial

1 Co-Investigator for BIVAFLO Registy (2006). To evaluate the Efficacy and Safety of BIVAFLO® as an Adjunctive Therapy During PCI in Moderate-high Risk ACS Patients with Provisional GP IIb/IIIa Inhibitors Use. Trial Completed.
2 Co-Investigator for CORREL + C Trial (2006). The COREL C Registry: A Multicentre Post Marketing Surveillance for Clinical and Angiographic Evaluation of Corel C Stent. Trial Completed.
3 Co-Investigator for POLYCAP Trial at The Heart Care Clinic/CIMS Ahmedabad(2007). A Randomized Double blind controlled trial of the efficacy And safety of POLYCAP Vs its components in subjects With at least one additional cardiovascular risk factor. Trial Completed.
4 Co-Investigator for ACUNOVA Trial (2006-2007). A phase III, open label, multi-centric, parallel group,  Randomized study to evaluate the safety and efficacy of Abciximab in Indian patients scheduled for Percutaneuos Coronary Intervention. Trial Completed.
5 Co – Investigator for ZYHI Trial at The Heart Care Clinic Ahmedabad (2007) Trial Completed.
6 Co-Investigator for “The Dyslipidemia REMAINS Study” – A multicenter, prospective, observational study of lipid profiles and treatment patterns at presentation and after 12 weeks of statin therapy among Indian adults presenting with first coronary event, ongoing at CIMS Hospital Ahmedabad (2012). Trial Completed.
7 Co-Investigator for HF-Registry at CIMS Hospital, Ahmedabad (2012). A prospective, open label, multi-centric, observational registry for heart failure patients across India. Recruitment Ongoing.
8 Co- Investigator for “The International Polycap Study 3” (TIPS 3) at CIMS Hospital, Ahmedabad (2012) A randomized double-blind placebo-controlled trial for the evaluation of a polycap, low dose aspirin and vitamin D supplementation in primary prevention. Recruitment Ongoing.
9 Co-Investigator for BioMime Morph at CIMS Hospital, Ahmedabad (2016). A prospective, single-arm, multi-centre, observational, real world, post-marketing surveillance to evaluate safety and performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System for very long coronary lesions. Recruitment Ongoing.
10 Co-Investigator for TREASURE at CIMS Hospital, Ahmedabad (2015). A non-inTeRventional prospEctive observationAl Study to Understand the usage pattern of Ticagrelor in Indian patients with acute coronaRy syndromE (TREASURE). Follow Up Ongoing.

    Get a Consultation

    We’ve Been Healing Hearts For Over 20 years

    Dr. Milan Chag is a director at the Heart Failure Clinic at CIMS Hospital and is rated amongst the best cardiologists in Ahmedabad and Gujarat. He is rated the top cardiologist in Rajkot, where he is originally from. 

    Patient Testimonials

    “Dr. Milan chug sir is not only one of the best cardiologist but a very simple person down to earth. we including our next to god have great faith in his abilities…xoxo”

    YUG MODHA

    “Dr. Milan Chag is not only one of the best cardiologist but a very simple and down to earth person. We, including my late father have great faith in his abilities.”

    NARENDRA LODHA

    “Great human being..Great teacher.. we taught many things from him for work n life also.Thanks 4 everything.”‘

    MOIN SHAIKH

    Contact


    OPD 10, CIMS Hospital, Science City Road, Sola, Ahmedabad 380060, Gujarat, India.

    +91 7069000000

    For appointment Call
    +91-98250 66661
    +91-79-3010 1008
    +91-79-3010 1200

    Ambulance & Emergency
    +91-97234 50000

    milan.chag@cims.me

    For appointment on email : ope.rec@cimshospital.org